Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Rafael Daltro de Oliveira"'
Autor:
Moysés Antonio Porto-Soares, Rafael Daltro de Oliveira, Gabriel Macedo Cortopassi, João Agostinho Machado-Neto, Leonardo Carvalho Palma, Lorena Lobo de Figueiredo-Pontes
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 42, Iss 3, Pp 238-244 (2020)
Background: The classical BCR-ABL1-negative myeloproliferative neoplasms (MPNs) are Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF). In developing countries, there are few reports that truly reveal the clinical
Externí odkaz:
https://doaj.org/article/7ad2024fe187464880cff1a3614dd949
Autor:
Dikelele Elessa, Lin-Pierre Zhao, Rafael Daltro de Oliveira, Nabih Maslah, Juliette Soret, Emmanuelle VERGER, Clémence Marcault, Nathalie Parquet, Pierre Fenaux, Lionel Adès, Emmanuel Raffoux, Stéphane GIRAUDIER, Olivier Fain, Bruno Cassinat, Jean-Jacques Kiladjian, Arsène MEKINIAN, Lina Benajiba
There are few data regarding the association of autoimmune and inflammatory diseases (AID) with Philadelphia negative myeloproliferative neoplasms (MPN). In this retrospective study, we describe the prevalence, clinical and biological features and ou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c710f33b766c0622fee98b209322c59a
https://doi.org/10.21203/rs.3.rs-2526712/v1
https://doi.org/10.21203/rs.3.rs-2526712/v1
Autor:
Corinne Maréchal, Céleste Lebbé, Lina Benajiba, Jin Huang, Rafael Daltro De Oliveira, Anne Bergeron, Nathalie Langner, Abdennour Chellah, Souhil Allaoua, Jean-Jacques Kiladjian, Juliette Soret-Dulphy, Zineb Ghrieb, Majdi Jebali, Florène François
Publikováno v:
Therapies
Resume Contexte Le Centre d’investigations cliniques de l’Hopital Saint-Louis (CIC-1427) est une structure dediee qui accueille des patients inclus dans des essais cliniques essentiellement de phases precoces (premiere administration chez l’hom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb2e3383048611bc15c9976104fe33b1
https://doi.org/10.1016/j.therap.2021.02.003
https://doi.org/10.1016/j.therap.2021.02.003
Autor:
Hélène Pasquer, Rafael Daltro De Oliveira, Juliette Soret, Nabih Maslah, Lin-Pierre Zhao, Clemence Marcault, Marine Cazaux, Nicolas Gauthier, Emmanuelle Verger, Nathalie Parquet, William Vainchenker, Emmanuel Raffoux, Stephane Giraudier, Bruno Cassinat, Jean-Jacques Kiladjian, Lina Benajiba
Publikováno v:
Blood. 140:830-831
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e74c7cce6d9f3c91e008b41a2e043a75
https://doi.org/10.1182/blood-2022-160329
https://doi.org/10.1182/blood-2022-160329
Autor:
Nabih Maslah, Blandine Roux, Nina Kaci, Emmanuelle Verger, Rafael Daltro De Oliveira, Hélène Pasquer, Nicolas Gauthier, Juliette Soret, Saravanan Ganesan, Panhong Gou, Frank Ling, Nathalie Parquet, William Vainchenker, Emmanuel Raffoux, Rose Ann Padua, Stephane Giraudier, Alexandre Puissant, Camille Lobry, Jean-Jacques Kiladjian, Bruno Cassinat, Lina Benajiba
Publikováno v:
Blood. 140:795-796
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d96e405a012f3318c13f85255461622f
https://doi.org/10.1182/blood-2022-167719
https://doi.org/10.1182/blood-2022-167719
Autor:
Zineb, Ghrieb, Souhil, Allaoua, Jin, Huang, Nathalie, Langner, Florène, François, Corinne, Maréchal, Majdi, Jebali, Céleste, Lebbé, Abdennour, Chellah, Anne, Bergeron, Jean-Jacques, Kiladjian, Rafael, Daltro De Oliveira, Juliette, Soret-Dulphy, Lina, Benajiba
Publikováno v:
Therapie
Contexte Le Centre d’investigations cliniques de l’Hôpital Saint-Louis (CIC-1427) est une structure dédiée qui accueille des patients inclus dans des essais cliniques essentiellement de phases précoces (première administration chez l’homme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d96e3d4909458b174c194773cc5bafe1
https://pubmed.ncbi.nlm.nih.gov/33640116
https://pubmed.ncbi.nlm.nih.gov/33640116
Autor:
Lin-Pierre Zhao, Marine Cazaux, Nabih Maslah, Rafael Daltro De Oliveira, Emmanuelle Verger, Juliette Soret-Dulphy, Clemence Marcault, Nathalie Parquet, Christine Dosquet, William Vainchenker, Emmanuel Raffoux, Stephane Giraudier, Jean-Jacques Kiladjian, Bruno Cassinat, Lina Benajiba
Publikováno v:
Blood. 138:317-317
Introduction: Although myeloproliferative neoplasms (MPN) are driven by three mutually exclusive driver mutations (JAK2, CALR and MPL), targeted deep sequencing studies identified multiple additional somatic mutations potentially impacting MPN evolut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e2b65b422e8e3176cd4a8559ee00b1b8
https://doi.org/10.1182/blood-2021-149473
https://doi.org/10.1182/blood-2021-149473
Autor:
Lionel Ades, Emmanuelle Verger, Nabih Maslah, Juliette Soret-Dulphy, Arsène Mekinian, Emmanuel Raffoux, Rafael Daltro De Oliveira, Pierre Fenaux, Clemence Marcault, Dikelele Elessa, Bruno Cassinat, Olivier Fain, Nathalie Parquet, Stéphane Giraudier, Lina Benajiba, Jean-Jacques Kiladjian, Lin-Pierre Zhao
Publikováno v:
Blood. 138:1496-1496
Introduction: Auto-immune and Inflammatory Diseases (AID) have been associated with myeloproliferative neoplasms (MPN) in a large population-based study (Kristinsson et al. Haematologica 2010). In myelodysplastic syndromes (MDS) and chronic myelomono
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::965f494c06d961ed4808375195b280bd
https://doi.org/10.1182/blood-2021-152302
https://doi.org/10.1182/blood-2021-152302
Autor:
Lina Benajiba, Christine Chomienne, Juliette Soret-Dulphy, William Vainchenker, Rafael Daltro De Oliveira, Jean-Jacques Kiladjian, Emmanuelle Verger, Bruno Cassinat, Lin-Pierre Zhao, Clemence Marcault, Emmanuel Raffoux, Nabih Maslah, Nicolas Gauthier, Nathalie Parquet
Publikováno v:
Blood. 136:35-36
Background: Although patients with MPN may achieve complete hematological remission (CHR) with cytoreductive therapy (CRT), lifelong treatment represents a major burden for these chronically ill patients. IFN has emerged as a major MPN therapy though
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::73dba31d396ed506763a88a9c2f129b6
https://doi.org/10.1182/blood-2020-141223
https://doi.org/10.1182/blood-2020-141223
Autor:
Rafael Daltro De Oliveira, Juliette Soret-Dulphy, Bruno Cassinat, Jean-Jacques Kiladjian, Delphine Rea, Clemence Marcault, Jean-Marc Zini, Lin-Pierre Zhao, Lina Benajiba, Emmanuel Raffoux, Nicolas Gauthier, Nathalie Parquet, Stéphane Giraudier
Publikováno v:
Blood. 136:8-8
Introduction: Ruxolitinib (RUX) is a JAK 1/2 inhibitor approved for the treatment of intermediate and high-risk primary or secondary MF. In addition to the intrinsic immune system modulation in MF patients, JAK inhibition exerts an immunosuppressive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cc7d6ab370220d5bf91c5e0acb5545cb
https://doi.org/10.1182/blood-2020-141260
https://doi.org/10.1182/blood-2020-141260